UroGen Pharma EBIT

The latest EBIT for URGN is $-75M as of June 2026. That compares with $-120M in the prior-year period — up 38.1% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside UroGen Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, URGN's EBIT moved from $-120M to $-75M — a 38.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in UroGen Pharma's operating scale or balance-sheet position.

Against Healthcare companies, URGN currently prints $-75M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at UroGen Pharma's growth, margins, and balance sheet.

A EBIT figure of $-75M for URGN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting URGN's EBIT ($-75M), review year-over-year change from $-120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.